Zai Lab Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZLAB Nasdaq 2836 www.zailaboratory.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zai Lab Limited

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint - Jul 1st, 2025 3:32 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading - Jun 30th, 2025 8:33 am
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Jun 30th, 2025 7:05 am
Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Up 5% for Week - Jun 27th, 2025 8:50 am
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - Jun 24th, 2025 8:38 am
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis - Jun 20th, 2025 2:04 pm
Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading - Jun 17th, 2025 8:28 am
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Jun 13th, 2025 5:00 am
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Jun 2nd, 2025 5:00 am
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - May 31st, 2025 1:08 pm
Zai Lab Announces Participation in Investor Conferences in June 2025 - May 30th, 2025 5:30 am
Exploring 3 High Growth Tech Stocks In The US Market - May 19th, 2025 11:45 am
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - May 19th, 2025 5:00 am
Zai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - May 10th, 2025 7:23 am
Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - May 9th, 2025 1:11 am
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say - May 8th, 2025 8:00 am
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates - May 8th, 2025 4:00 am
Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts - May 5th, 2025 3:58 pm
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 - Apr 25th, 2025 11:12 am
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Apr 23rd, 2025 8:56 am